Literature DB >> 23343161

Physicochemical property trends of marketed prodrugs.

Margaret S Landis1.   

Abstract

Many prodrug reviews describe specific examples of the successful application of prodrug technology to produce blockbuster drugs, such as simvastatin, omeprazole, acyclovir and enalapril. These reviews are helpful to understand the previous success stories and case histories of prodrug technology. The aim of the current review seeks to more clearly define quantitative trends in the changes in the physicochemical property parameters between the successful prodrug and the active parent molecule. This information can serve to guide medicinal chemists toward more successful pharmaceutical prodrugs in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343161     DOI: 10.4155/tde.12.150

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  4 in total

1.  The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.

Authors:  D C Pryde; N A Swain; P A Stupple; C W West; B Marron; C J Markworth; D Printzenhoff; Z Lin; P J Cox; R Suzuki; S McMurray; G J Waldron; C E Payne; J S Warmus; M L Chapman
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

Review 2.  Self-assembling prodrugs.

Authors:  Andrew G Cheetham; Rami W Chakroun; Wang Ma; Honggang Cui
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

3.  Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors.

Authors:  Dawn M George; Raymond J Huntley; Kevin Cusack; David B Duignan; Michael Hoemann; Jacqueline Loud; Regina Mario; Terry Melim; Kelly Mullen; Gagandeep Somal; Lu Wang; Jeremy J Edmunds
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

4.  Personalized medicine: myth or reality? The position of Russian clinical pharmacologists.

Authors:  Anna S Zhestovskaja; Vladimir G Kukes; Dmitry A Sychev
Journal:  EPMA J       Date:  2013-05-11       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.